138 related articles for article (PubMed ID: 32088380)
1. Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration.
Pellegrini C; Ippolito C; Segnani C; Dolfi A; Errede M; Virgintino D; Fornai M; Antonioli L; Garelli F; Nericcio A; Colucci R; Cerri S; Blandini F; Blandizzi C; Bernardini N
Neurobiol Dis; 2020 Jun; 139():104821. PubMed ID: 32088380
[TBL] [Abstract][Full Text] [Related]
2. Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease.
Levandis G; Balestra B; Siani F; Rizzo V; Ghezzi C; Ambrosi G; Cerri S; Bonizzi A; Vicini R; Vairetti M; Ferrigno A; Pastoris O; Blandini F
Neurogastroenterol Motil; 2015 Dec; 27(12):1783-95. PubMed ID: 26433214
[TBL] [Abstract][Full Text] [Related]
3. An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis.
Ippolito C; Segnani C; Errede M; Virgintino D; Colucci R; Fornai M; Antonioli L; Blandizzi C; Dolfi A; Bernardini N
J Cell Mol Med; 2015 Feb; 19(2):485-500. PubMed ID: 25521239
[TBL] [Abstract][Full Text] [Related]
4. Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Pellegrini C; Fornai M; Colucci R; Tirotta E; Blandini F; Levandis G; Cerri S; Segnani C; Ippolito C; Bernardini N; Cseri K; Blandizzi C; Haskó G; Antonioli L
J Neuroinflammation; 2016 Jun; 13(1):146. PubMed ID: 27295950
[TBL] [Abstract][Full Text] [Related]
5. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Pellegrini C; Antonioli L; Colucci R; Tirotta E; Gentile D; Ippolito C; Segnani C; Levandis G; Cerri S; Blandini F; Barocelli E; Ballabeni V; Bernardini N; Blandizzi C; Fornai M
Neuropharmacology; 2017 Sep; 123():22-33. PubMed ID: 28526609
[TBL] [Abstract][Full Text] [Related]
6. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson's disease rats.
Zhang X; Li Y; Liu C; Fan R; Wang P; Zheng L; Hong F; Feng X; Zhang Y; Li L; Zhu J
Transl Res; 2015 Aug; 166(2):152-62. PubMed ID: 25766133
[TBL] [Abstract][Full Text] [Related]
7. Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis.
Ippolito C; Colucci R; Segnani C; Errede M; Girolamo F; Virgintino D; Dolfi A; Tirotta E; Buccianti P; Di Candio G; Campani D; Castagna M; Bassotti G; Villanacci V; Blandizzi C; Bernardini N
J Crohns Colitis; 2016 Oct; 10(10):1194-204. PubMed ID: 26995183
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Zn
Tamano H; Nishio R; Morioka H; Takeda A
Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
[TBL] [Abstract][Full Text] [Related]
9. Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats.
Fornai M; Pellegrini C; Antonioli L; Segnani C; Ippolito C; Barocelli E; Ballabeni V; Vegezzi G; Al Harraq Z; Blandini F; Levandis G; Cerri S; Blandizzi C; Bernardini N; Colucci R
J Pharmacol Exp Ther; 2016 Feb; 356(2):434-44. PubMed ID: 26582732
[TBL] [Abstract][Full Text] [Related]
10. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.
Garrido-Gil P; Rodriguez-Perez AI; Dominguez-Meijide A; Guerra MJ; Labandeira-Garcia JL
Mol Neurobiol; 2018 Sep; 55(9):7297-7316. PubMed ID: 29404956
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
13. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M
Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474
[TBL] [Abstract][Full Text] [Related]
14. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk?
Vairetti M; Ferrigno A; Rizzo V; Ambrosi G; Bianchi A; Richelmi P; Blandini F; Armentero MT
Biochim Biophys Acta; 2012 Feb; 1822(2):176-84. PubMed ID: 22119596
[TBL] [Abstract][Full Text] [Related]
15. Central dopaminergic control of cell proliferation in the colonic epithelium.
Yu S; Peng HR; Zhang YK; Yin YQ; Zhou JW
Neurosci Res; 2022 Jul; 180():72-82. PubMed ID: 35257836
[TBL] [Abstract][Full Text] [Related]
16. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
Guo X; Liu T; Zhao D; Wang X; Liu D; He Y; Shan C; Kong Y; Hu W; Tao B; Sun L; Zhao H; Li S; Liu J
Neuroscience; 2017 Jul; 356():229-241. PubMed ID: 28504195
[TBL] [Abstract][Full Text] [Related]
17. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
18. Intestinal dysmotility after bowel resection in rats is associated with decreased ghrelin and vimentin expression and loss of intestinal cells of Cajal.
Sukhotnik I; Ben-Shahar Y; Pollak Y; Cohen S; Moran-Lev H; Koppelmann T; Gorenberg M
Am J Physiol Gastrointest Liver Physiol; 2021 Mar; 320(3):G283-G294. PubMed ID: 33325807
[TBL] [Abstract][Full Text] [Related]
19. Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.
Cui H; Elford JD; Alitalo O; Perez-Pardo P; Tampio J; Huttunen KM; Kraneveld A; Forsberg MM; Myöhänen TT; Jalkanen AJ
Neurobiol Aging; 2023 Sep; 129():62-71. PubMed ID: 37271045
[TBL] [Abstract][Full Text] [Related]
20. Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model.
Colucci M; Cervio M; Faniglione M; De Angelis S; Pajoro M; Levandis G; Tassorelli C; Blandini F; Feletti F; De Giorgio R; Dellabianca A; Tonini S; Tonini M
Auton Neurosci; 2012 Aug; 169(2):77-86. PubMed ID: 22608184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
